Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants : five-year follow-up of a randomized study

Autor: Georges Mourad, Peter Lang, Karl Martin Wissing, Pierre Merville, François Bayle, Rachel Hellemans, F. Berthoux, Jean-Paul Squifflet, Marc Hazzan, Christian Noel, Bernard Charpentier, Dominique Durand, Guy Touchard, M. Kessler, Daniel Abramowicz, Nacera Ouali

Publikováno v: American journal of transplantation
American Journal of Transplantation
American Journal of Transplantation, Wiley, 2015, 15 (7), pp.1923-32. ⟨10.1111/ajt.13191⟩

International audience; We previously reported a randomized controlled trial in which 227 de novo deceased-donor kidney transplant recipients were randomized to rabbit antithymocyte (rATG, Thymoglobulin) or daclizumab if they were considered to be at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::529bb5ca910daa606c0d5825cbff241b
https://hdl.handle.net/10067/1237360151162165141